CT9 Stock Overview
A clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Cardiol Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$2.16 |
| 52 Week High | CA$2.16 |
| 52 Week Low | CA$0.54 |
| Beta | 0.68 |
| 1 Month Change | 24.86% |
| 3 Month Change | 60.82% |
| 1 Year Change | 302.80% |
| 3 Year Change | -0.23% |
| 5 Year Change | n/a |
| Change since IPO | 4.99% |
Recent News & Updates
Recent updates
Shareholder Returns
| CT9 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 11.1% | 5.8% | 0.6% |
| 1Y | 302.8% | -17.7% | 5.4% |
Return vs Industry: CT9 exceeded the German Pharmaceuticals industry which returned -17.5% over the past year.
Return vs Market: CT9 exceeded the German Market which returned 7.3% over the past year.
Price Volatility
| CT9 volatility | |
|---|---|
| CT9 Average Weekly Movement | 16.7% |
| Pharmaceuticals Industry Average Movement | 5.6% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.4% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: CT9's share price has been volatile over the past 3 months.
Volatility Over Time: CT9's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | n/a | David Elsley | www.cardiolrx.com |
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure.
Cardiol Therapeutics Inc. Fundamentals Summary
| CT9 fundamental statistics | |
|---|---|
| Market cap | €148.71m |
| Earnings (TTM) | -€20.44m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-7.3x
P/E RatioIs CT9 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CT9 income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$30.22m |
| Earnings | -CA$30.22m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.44 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did CT9 perform over the long term?
See historical performance and comparison